Haemonetics (HAE) Set to Launch VASCADE MVP XL in US

Company Overview - Haemonetics Corporation has announced the full market release of its VASCADE MVP XL, a mid-bore venous closure system, now available to U.S. hospitals as part of its VASCADE portfolio [1][2] - The VASCADE MVP XL system is designed for procedures requiring 10-12F sheaths (up to 15F in outer diameter) and utilizes 58% more collagen and a larger disc compared to the previous VASCADE MVP system [3][6] - The system is intended for various procedures, including cryoablation, Pulsed Field Ablation (PFA), and Left Atrial Appendage Closure (LAAC) [3] Market Position and Prospects - The company is well-positioned to expand the indications for the VASCADE MVP XL system, targeting larger access points, which aligns with the growing vascular closure solutions market [2] - The global vascular closure devices market was valued at $1.75 billion in 2023 and is projected to reach $3.30 billion by 2033, with a CAGR of 6.55% [7] Recent Developments - Following positive feedback during a limited market release, Haemonetics aims to make the VASCADE MVP XL available to all U.S. hospitals promptly [5] - The company received CE Mark certification for the SavvyWire guidewire in July 2024, marking a significant step in its international expansion strategy [8] - In April 2024, Haemonetics acquired Attune Medical, expected to increase revenues by $35 million [10] Financial Performance - Year-to-date, Haemonetics shares have decreased by 13.5%, contrasting with the industry's growth of 5.8% [11]